Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 960-965

  Shah, S R ^a   Gressett Ussery, S M ^b   Dowell, J E ^c   Marley, E ^d   Liticker, J ^e   Arriaga, Y ^c   Verma, U ^c  

^a TEXAS TECH UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Administration; Bevacizumab; Colorectal cancer; Hypertension; Infusion; Proteinuria

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION;

EID: 84875617467     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds593     Document Type: Article

References (23)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
2. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
3. Willett CG, Boucher Y, di Tomaso E et al.. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
4. Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
5. Giantonio BJ, Catalano PJ, Meropol NJ et al.. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
6. Sandler A, Gray R, Perry MC et al.. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
7. Kreisl TN, Kim L, Moore K et al.. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-745.
8. Escudier B, Pluzanska A, Koralewski P et al.. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
9. Reidy DL, Chung KY, Timoney JP et al.. Bevacizumab 5 mg/kg can be infused safely over 10 min. J Clin Oncol 2007; 25: 2691-2695.
10. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49: e23-e29.
11. Roncone D, Satoskar A, Nadasdy T et al.. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nature clinical practice. Nephrology 2007; 3: 287-293.
12. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017.
13. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43: 490-501.
14. Avastin. [Package Insert]. South San Francisco, CA: Genentech, Inc; 2011.
15. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S12-154.
16. Gaspari F, Perico N, Remuzzi G. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis 2006; 47: 1-7.
17. Constantiner M, Sehgal AR, Humbert L et al.. A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. Am J Kidney Dis 2005; 45: 833-841.
18. Gross JL, de Azevedo MJ, Silveiro SP et al.. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176.
19. The. National Cancer Institute Common Toxicity Criteria (CTC) Version 3.0. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed 1 May 2012.
20. Kabbinavar FF, Schulz J, McCleod M et al.. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
21. Saltz LB, Clarke S, Diaz-Rubio E et al.. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
22. Tol J, Koopman M, Rodenburg CJ et al.. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008; 19: 734-738.
23. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al.. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.